Posts

Showing posts with the label tumor progression

Foods to Avoid Cancer

Image
While no single meal will kill cancer, a balanced and nutritious diet may substantially lower your risk. Here are some ideas on what meals to include and which to restrict or avoid by not only cancer patients or the general population who might be at higher risk. Foods to include Fruits and vegetables are rich in vitamins, minerals, and antioxidants that help protect against various types of cancer.  Whole grains: Foods like brown rice, quinoa, oats, and whole wheat contain fibre and other nutrients that are beneficial for overall health. Lentils and Pulses: Eating high-fibre foods reduces the risk of bowel cancer.  Lean proteins: Include sources like fish, poultry, beans, and tofu. Limit processed meats like bacon, sausage, and deli meats, which have been linked to an increased risk of cancer. Healthy fats: Choose sources like nuts, seeds, avocados, and olive oil. These fats have anti-inflammatory properties and can promote overall health. Herbs and spices: Many herbs and spi...

EMT Pathway in Tumor Progression

Image
Abstract Epithelial to mesenchymal transition pathway responsible for embryogenesis, organ development, and tumor metastasis is an important pathway in tumor progression. The gaining of mesenchymal properties such as migratory, invasive phenotype and losing the epithelial properties such as apical to basal polarity. EMT is a multi-step process i.e. from the gaining of mesenchymal features to the formation of a secondary tumor microenvironment through intravasation and extravasation of circulating tumor cells (CTCs). Loss or low E-cadherin expression is the major hallmark of this pathway. Various signaling pathways are involved in the induction of EMT that regulate it directly or indirectly. TGFβ, Wnt/β-Catenin, PI3K/Akt, STAT/LIV-1 signaling and Hedgehog signaling pathway are responsible for the induction of the EMT pathway through heterotypic signaling. Whereas GSK-3β, MTA3 repressor, and drugs such as Herceptin, erlotinib, and imatinib are responsible for the downregulation ...